Brief: Ambu Q2 Organic Revenue Growth 7.3%

Ambu A/S

06/05/2026 06:13

May 6 (Reuters) - Ambu A/S AMBUb.CO:

IN Q2 2025/26, AMBU DELIVERED ORGANIC REVENUE GROWTH OF 7.3%

Q2 GROWTH WAS DRIVEN BY CONTINUED STRONG PERFORMANCE IN THE MARKET‑LEADING ENDOSCOPY SOLUTIONS BUSINESS, WHICH GREW 13.8%

Q2 ANESTHESIA  PATIENT MONITORING (APM) DECLINED BY 2.5%

Q2 REPORTED EBIT (B.S.I.) WAS DKK 173M, CORRESPONDING TO AN EBIT MARGIN OF 11.0%

FOR FY 2025/26, CO NOW EXPECTS ORGANIC REVENUE GROWTH OF 10-12% (PREVIOUSLY 10-13%)

EBIT MARGIN GUIDANCE OF 12-14% REMAINS UNCHANGED

OUR LEGACY BUSINESSES, ANESTHESIA  PATIENT MONITORING, WERE WEAKER THAN EXPECTED, PULLING THE TOTAL REVENUE GROWTH DOWN

Source text

Further company coverage: [AMBUb.CO]

 (Gdansk Newsroom)

 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))